Why the study?
Does dextran-70, warfarin, or low-dose heparin prevent deep venous thrombosis and pulmonary embolism in patients undergoing total hip replacement?
Does dextran-70, warfarin, or low-dose heparin prevent deep venous thrombosis and pulmonary embolism in patients undergoing total hip replacement?
Warfarin completely prevented pulmonary embolism compared to dextran-70 and low-dose heparin in patients undergoing total hip replacement, despite similar rates of calf vein thrombosis across all groups.
Answers are grounded in this paper and cite their sources.
Warfarin warrants consideration for pulmonary embolism prophylaxis after hip replacement; confirms superiority to dextran-70 and heparin despite equivalent calf thrombosis rates.
In a randomized, controlled clinical study, dextran-70, warfarin, or low-dose heparin were administered to patients undergoing total hip replacement on one surgical unit in an attempt to prevent deep venous thrombosis and pulmonary embolism. Calf vein thrombosis was detected by the 125I-fibrinogen uptake test. None of the methods prevented calf vein thrombosis (dextran-70, 51%; warfarin, 58-6%; heparin, 52-6%). Pulmonary embolism was completely prevented in patients treated with warfarin but occurred in 4% of patients treated with dextran-70 and 15-5% of those treated with low-dose heparin. The incidence of complications of therapy was small and comparable in each group. It is suggested that calf vein thrombosis is a frequent and in itself a non-serious complication of total hip replacement surgery and that emphasis might be placed more usefully on prevention of pulmonary embolism.
No takes yet. Share an insight, caveat, or question.
Barber et al. (1977) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: